QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Accuray, Inc. (ARAY) Passes 600th Installation 0 comments
    Jan 11, 2012 10:18 AM | about stocks: ARAY

    Accuray Inc. yesterday announced that it has surpassed 600 installations of its CyberKnife Robotic Radiosurgery System and TomoTherapy System globally. The numbers were presented at the 30th annual J.P. Morgan Healthcare Conference in San Francisco by Accuray CEO Euan Thompson.

    Accuray is a Sunnyvale, CA company that focuses on developing and manufacturing devices intended for radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. Their CyberKnife and TomoTherapy systems have assisted over 200,000 patients worldwide.

    With over 600 installations in 33 countries in approximately ten years, Accuray has solidified their marketplace position. Accuray is currently pursuing opportunities that will see replacement units taking over for the earliest installed CyberKnife and TomoTherapy systems. With a growing demand for effective and efficient radiation oncology treatments, Accuray seems confident that momentum will continue to further push year-over-year growth.

    Euan S. Thomson, president and CEO of Accuray, said, “Accuray is committed to advancing our product lines to meet the ever-changing needs of our customer base, as well as the patients fighting cancer. The proven advantages of Accuray’s treatment systems are behind the growing global adoption of both the CyberKnife and TomoTherapy systems by new as well as existing customers. Our proven track record solidifies Accuray’s position in the growing radiation oncology market.”

    Raj Denhoy, managing director, equity research at Jefferies & Co., said, “Through the acquisition of TomoTherapy, Accuray is well positioned with two cutting edge and complementary technologies in a growing radiation oncology market. With an established and growing installed customer base, we anticipate continued good growth driven by both competitive wins as well as replacements.”

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ARAY
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.